Published in PLoS Pathog on February 10, 2011
Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05
Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression. AIDS (2013) 2.04
Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity (2013) 2.00
Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J Virol (2011) 1.57
CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. J Immunol (2012) 1.57
Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol (2012) 1.23
The T-cell response to HIV. Cold Spring Harb Perspect Med (2012) 1.20
Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J Virol (2012) 1.13
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates. Vaccines (Basel) (2014) 1.04
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. J Virol (2014) 1.03
Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood (2012) 1.03
Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages. J Virol (2012) 1.00
CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis. Immunol Rev (2013) 1.00
Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection. PLoS Pathog (2014) 0.95
HIV-Host Interactions: Implications for Vaccine Design. Cell Host Microbe (2016) 0.93
The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization. PLoS One (2012) 0.92
PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. J Clin Invest (2013) 0.90
Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. PLoS Pathog (2015) 0.89
T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load. Eur J Immunol (2012) 0.88
Structured observations reveal slow HIV-1 CTL escape. PLoS Genet (2015) 0.88
Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Vaccine (2012) 0.86
Broad and persistent Gag-specific CD8+ T-cell responses are associated with viral control but rarely drive viral escape during primary HIV-1 infection. AIDS (2015) 0.86
Combination of immune and viral factors distinguishes low-risk versus high-risk HIV-1 disease progression in HLA-B*5701 subjects. J Virol (2012) 0.85
The emerging role of leukocyte immunoglobulin-like receptors (LILRs) in HIV-1 infection. J Leukoc Biol (2011) 0.85
Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. AIDS Res Hum Retroviruses (2012) 0.85
Functional avidity and IL-2/perforin production is linked to the emergence of mutations within HLA-B*5701-restricted epitopes and HIV-1 disease progression. J Immunol (2014) 0.83
Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. Retrovirology (2014) 0.82
The HIV treatment cascade in acutely infected people: informing global guidelines. Curr Opin HIV AIDS (2015) 0.81
Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. J Virol (2016) 0.81
Immunogenetics of small ruminant lentiviral infections. Viruses (2014) 0.80
Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition. J Virol (2014) 0.79
Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection. PLoS Pathog (2016) 0.79
Reversion and T cell escape mutations compensate the fitness loss of a CD8+ T cell escape mutant in their cognate transmitted/founder virus. PLoS One (2014) 0.78
Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. J Infect Dis (2017) 0.78
Recent update in HIV vaccine development. Clin Exp Vaccine Res (2016) 0.76
Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. Nat Rev Drug Discov (2016) 0.76
Enhancement of viral escape in HIV-1 Nef by STEP vaccination. AIDS (2016) 0.75
HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. Mol Ther (2017) 0.75
Baseline CD4+ T cell counts correlates with HIV-1 synonymous rate in HLA-B*5701 subjects with different risk of disease progression. PLoS Comput Biol (2014) 0.75
Co-operation between strain-specific and broadly neutralizing responses limited viral escape, and prolonged exposure of the broadly neutralizing epitope. J Virol (2017) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15
Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (1991) 10.85
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med (2006) 8.18
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A (1997) 8.05
Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (2002) 7.41
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 7.33
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2008) 6.17
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol (2004) 5.18
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med (2002) 5.17
Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A (2008) 4.71
HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A (2005) 4.02
Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med (2008) 3.48
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
CD8+ T cell efficacy in vaccination and disease. Nat Med (2008) 3.20
Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med (1998) 3.03
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol (2006) 2.70
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59
Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood (2009) 2.33
The rational design of an AIDS vaccine. Cell (2006) 2.11
Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J Exp Med (2009) 2.03
CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog (2010) 1.99
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol (2010) 1.81
Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J Virol (2008) 1.53
Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point. J Immunol (2009) 1.49
In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog (2010) 1.48
Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. J Immunol (2009) 1.37
Estimating Costs and Benefits of CTL Escape Mutations in SIV/HIV Infection. PLoS Comput Biol (2006) 1.36
Post-step modifications for research on HIV vaccines. AIDS (2009) 1.26
CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. AIDS (2005) 1.26
Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status. PLoS One (2008) 1.21
In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques. J Virol (2007) 1.11
Secretion of MIP-1β and MIP-1α by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage. Cell Immunol (2010) 0.95
HLA-B molecules target more conserved regions of the HIV-1 proteome. AIDS (2010) 0.93
Epigenetic regulation of CD8(+) T-lymphocyte mediated suppression of HIV-1 replication. Virology (2010) 0.90
Identification and characterization of HIV-1 CD8+ T cell escape variants with impaired fitness. J Infect Dis (2008) 0.88
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 13.15
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol (2008) 11.65
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med (2006) 8.18
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol (2004) 7.37
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol (2008) 7.14
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2002) 6.73
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep (2008) 6.02
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol (2005) 5.83
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol (2003) 5.36
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med (2012) 4.74
Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A (2008) 4.71
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science (2007) 4.60
Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature (2003) 4.60
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (2013) 4.60
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat Med (2006) 4.41
Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest (2008) 4.30
Advantage of rare HLA supertype in HIV disease progression. Nat Med (2003) 4.08
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology (2004) 3.98
Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med (2009) 3.94
Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator. Cell (2006) 3.73
The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72
T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity (2004) 3.69
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 3.65
Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med (2003) 3.60
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A (2009) 3.58